Veradermics, Incorporated (MANE)
| Market Cap | 4.09B |
| Revenue (ttm) | n/a |
| Net Income | -104.29M |
| EPS | -6.44 |
| Shares Out | 41.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 623,539 |
| Open | 102.30 |
| Previous Close | 101.81 |
| Day's Range | 97.00 - 102.41 |
| 52-Week Range | 32.00 - 131.24 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 163.50 (+66.96%) |
| Earnings Date | Aug 11, 2026 |
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDM... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $163.5, which is an increase of 66.96% from the latest price.
News
Veradermics Earnings release: Q2 2026
Veradermics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Veradermics Quarterly report: Q2 2026
Veradermics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Veradermics sees cash runway into 2030
Cash, cash equivalents, and marketable securities totaled $819.9 million as of June 30, 2026 including net proceeds from our follow-on offering completed in the second quarter 2026. Veradermics (MANE)...
Veradermics reports Q2 net loss ($23.5M) vs. ($15.6M) last year
“In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the program. The positive Phase 2…
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics registers to sell 16.77M shares of common stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 16.77M shares of common stock. The company is not selling any…
Veradermics Registration statement: Registration filing
Veradermics filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Veradermics presents data from subgroup analysis of Phase 2/3 VDPHL01 study
Veradermics (MANE) announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in…
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics price target raised to $160 from $135 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $160 from $135 and keeps a Buy rating on the shares. The firm says the company’s Study 207 showed “robust”…
B. Riley Analyst Initiates Coverage of Veradermics Stock (MANE) With a Buy Rating
Veradermics stock soared on Wednesday after analyst Mayank Mamtani initiated coverage of the company’s shares.
Veradermics Transcript: Study result
Study 207 demonstrated that VDPHL01, an oral extended-release minoxidil, produced rapid, robust, and visible hair regrowth in women with pattern hair loss, with nearly 90% reporting improvement and a favorable safety profile. The results position VDPHL01 as a potential first FDA-approved oral treatment for this large, underserved population.
Veradermics Press release: Study result
Veradermics issued a press release on July 15, 2026, disclosing material business information to investors.
Veradermics Slides: Study result
Veradermics has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Veradermics announces results from Phase 2 trial of VDPHL01
Veradermics (MANE) announced positive topline results from its open-label Phase 2 clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-...
Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics initiated with a Buy at B. Riley
B. Riley initiated coverage of Veradermics (MANE) with a Buy rating and $170 price target The firm views the company’s lead asset VDPHL01, an extended-release oral minoxidil, as having a…
Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics price target raised to $182 from $138 at Jefferies
Jefferies raised the firm’s price target on Veradermics (MANE) to $182 from $138 and keeps a Buy rating on the shares. The firm expects VDPHL01 Phase 2 female pattern hair…
Veradermics initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Veradermics (MANE) with an Outperform rating and $135 price target
Veradermics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong phase II/III results for an extended-release oral minoxidil tablet show rapid, consistent hair growth and high tolerability in male pattern hair loss, with female trials underway. Market research reveals high unmet need and willingness to adopt, especially among women.
Veradermics Transcript: Jefferies Global Healthcare Conference 2026
Pattern hair loss affects 80 million in the U.S., with significant unmet need and dissatisfaction with current treatments. Recent clinical trial data show strong efficacy and safety for a new oral therapy, with high adoption intent among physicians and patients. Upcoming milestones include additional male and first female data releases.
Veradermics initiated with a Buy at Needham
Needham initiated coverage of Veradermics (MANE) with a Buy rating and $136 price target The company’s VDPHL01, a late-stage ER minoxidil product candidate, is well positioned to become the first…
Veradermics to Present at Upcoming June Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...